Pycnogenol® improvements in asthma management

Panminerva Medica

Volumn 53, Issue 3 SUPPLEMENT, 2011, Pages 57-64

  Belcaro, G ^a   Luzzi, R ^a   Cesinaro Di Rocco, P ^a   Cesarone, M R ^a   Dugall, M ^a   Feragalli, B ^a   Errichi, B M ^a   Ippolito, E ^a   Grossi, M G ^a   Hosoi, M ^a   Errichi, S ^a   Cornelli, U ^a   Ledda, A ^a   Gizzi, G ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Asthma; Inhalation.; Pycnogenol

Indexed keywords

ANTIASTHMATIC AGENT; CORTICOSTEROID; FLAVONOID; PLANT EXTRACT; PYCNOGENOLS;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYTOTHERAPY; PINE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; FLAVONOIDS; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PINUS; PLANT EXTRACTS; TREATMENT OUTCOME;

EID: 84859461933     PISSN: 00310808     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Oppenheimer J. The new mantra of asthma care-control. Ann Allergy Asthma Immunol 2007; 98: 205-6.
2. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008; 31: 143-78.
3. Expert panel report 3 (EPR-3): Guidelines for the diagnosis and management of asthma - summary report 2007. J Allergy Clin Immunol 2007; 120: 94-138.
4. Allen DB. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr 2006;53:101-10. (Pubitemid 44415932)
5. Marguet C, Couderc L, Lubrano M. Adverse events of inhaled steroids in childhood. Arch Pediatr 2004; 11 (Suppl 2): 113s-9s. (Pubitemid 39061205)
6. Adkinson NF Jr. Con: Immunotherapy is not clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001; 164: 2140-1, discussion 2141-2.
7. Barnes PJ. Is immunotherapy for asthma worthwhile? N Engl J Med 1996;334:531-2. (Pubitemid 26067745)
8. Bousquet J. Pro: Immunotherapy is clinically indicated in the management of allergic asthma. Am J Respir Crit Care Med 2001; 164: 2139-40, discussion 2141-2.
9. Norman PS. Is there a role for immunotherapy in the treatment of asthma? Yes. Am J Respir Crit Care Med 1996; 154: 1225-6.
10. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003; 4: CD001186.
11. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61:843-8. (Pubitemid 43893985)
12. Adkinson NF Jr, Eggleston PA, Eney D, Goldstein EO, Schuberth KC, Bacon JR et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997;336:324-31. (Pubitemid 27057182)
13. Özdemir C,Yazi D, Gocmen I.Yesil O, Aydogan M, Semic-Jusufagic A et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007;18:508-15. (Pubitemid 47206743)
14. Pham-Thi N, Scheinmann P, Fadei R, Combebias A, Andre C. Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures. Pediatr Al-lergy Immunol 2007;18:47-57. (Pubitemid 46232283)
15. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: A randomized controlled trial. J Allergy Clin Immunol 2010; 126: 942-9.
16. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol®a herbal medication with a diverse clinical pharmacology. Int J Clin Pharmacol Ther 2002;40:158-68. (Pubitemid 34296383)
17. Canali R, Comitato R, Schonlau F, Virgili F. The anti-inflammatory pharmacology of Pycnogenol®in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol. 2009; 9: 1145-9.
18. Hosseini S, Pishnamazi S, Sadrzadeh SM, Farid F, Farid R, Watson RR. Pycnogenol®® in the management of asthma. J Med Food 2001; 4: 201-9.
19. Lau BH, Riesen SK, Truong KP, Lau EW, Rohdewald P, Barreta RA. Pycnogenol® as an adjunct in the management of childhood asthma. J Asthma 2004;41:825-32. (Pubitemid 40019134)
20. Wilson D, Evans M, Guthrie N, Sharma P, Baisley J, Schonlau F, Burki C. A randomized, double-blind, placebo-controlled exploratory study to evaluate the potential of Pycnogenol®for improving allergic rhinitis symptoms. Phytother Res. 2010; 24: 1115-9.
21. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836-44. (Pubitemid 39346477)
22. Jorres RA, Nowak D, Kirsten D, Gronke L, Magnussen H. A short protocol for methacholine provocation testing adapted to the Rosenthal-Chai dosimeter technique. Chest 1997;111:866-9. (Pubitemid 27171454)
23. Pasche O, Cornuz J, Lazor R. [Management of asthma in primary care medicine J Rev Med Suisse 2010; 6: 2286-91.
24. O'Byrne PM, Reddel HK, Eriksson G, Ostlund O, Peterson S, Sears MR et al. Measuring asthma control: A comparison of three classification systems. Eur Respir J. 2010; 36: 269-76.
25. Steurer-Stey C, Russi EW, Steurer J. Complementary and alternative medicine in asthma: Do they work? Swiss Med Wkly. 2002; 132: 338-44.
26. Engler RJ, With CM, Gregory PJ, Jellin JM. Complementary and alternative medicine for the allergist-immunologist: Where do I start? J Allergy Clin Immunol. 2009; 123: 309-16.
27. Oliff H. Scientific and clinical monograph for Pycnogenol® The American Botanical Council, USA. 2010.
28. Grimm T, Chovanová Z, Muchová J, Sumegová K, Liptáková A, Duracková Z, Högger P. Inhibition of NF-kappaB activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol®J Inflamm (Lond). 2006; 27; 3: 1.
29. Barnes PJ. Biochemical basis of asthma therapy. J Biol Chem. 2011; 286: 32899-905.